Evolus (EOLS) Total Debt Growth (1y) (2019 - 2026)
Evolus (EOLS) Total Debt Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 41.53% |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 7.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.75% |
| Mar 31, 2026 | 28.41% |
| Dec 31, 2025 | 20.24% |
| Sep 30, 2025 | 20.27% |
| Jun 30, 2025 | 20.31% |
| Mar 31, 2025 | 0.97% |
| Dec 31, 2024 | 0.95% |
| Sep 30, 2024 | 27.46% |
| Jun 30, 2024 | 27.51% |
| Mar 31, 2024 | 67.44% |
| Dec 31, 2023 | 67.45% |
| Sep 30, 2023 | 32.61% |
| Jun 30, 2023 | 32.54% |
| Mar 31, 2023 | 0.93% |
| Dec 31, 2022 | 0.92% |
| Dec 31, 2021 | -4.25% |
| Dec 31, 2020 | 1.19% |
| Sep 30, 2020 | 318.55% |
| Jun 30, 2020 | 326.04% |
| Mar 31, 2020 | 1.77% |